Roivant Sciences reported a quiet Q1 2026 but anticipates a busy second half with the expected launch of brepocitinib by September and upcoming pipeline data. The company also received a significant $950 million settlement from Moderna, bolstering its cash position, which is a positive for future R&D and operations.
This 8-K filing provides a transcript of Roivant Sciences' Q1 2026 earnings call, highlighting key operational and financial updates. The most significant news is the anticipated launch of brepocitinib by September, which is a major commercial catalyst for ROIV. Additionally, the company received a substantial $950 million settlement from Moderna, significantly improving its cash position to just under $4 billion, which provides financial flexibility for ongoing R&D and potential future acquisitions. While Q1 was quiet, the outlook for the second half of 2026 is packed with potential catalysts, including top-line data from other pipeline candidates. For traders, the imminent brepocitinib launch and strong cash balance present a short-term opportunity, while ongoing litigation against Pfizer and BioNTech could be a long-term risk or opportunity depending on the outcome.